Condition: Bone Pain · Metastatic Bone Tumor · Bone Metastases in Subjects With Advanced Cancer · Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.
This description comes directly from the study's public registry record.
Sahar Khan · 248-469-2985 · sahar.khan@telixpharma.com
Sapna Shah, MD · sapna.shah@telixpharma.com
Always discuss trial participation with your own doctor first.
| Biogenix Molecular, LLC, CIRA Health | Miami, Florida, United States | Recruiting |
| NovaCure | Miami, Florida, United States | Recruiting |
| Houston Metro Urology | Houston, Texas, United States | Recruiting |
| Oncology Consultants | Houston, Texas, United States | Recruiting |
| Excel Diagnostics and Nuclear Oncology Center | Houston, Texas, United States | Recruiting |
| University of Texas Medical Branch at Galveston (UTMB) | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07197645